Introduction
The liver efficiently eliminates a variety of endogenous and exogenous organic anions from the blood circulation, which then undergo metabolism and/or biliary excretion in the liver. The hepatic uptake process is the most important step in their overall disposition by the liver. According to the conventional "free-drug" hypothesis, it has been assumed that the level of unbound ligand governs the hepatic uptake rate (Wilkinson and Shand, 1975; Shand et al., 1976) . However, it is a distinguishing feature of the liver that the hepatic uptake of organic anions is very efficient despite these organic anions being avidly bound to serum albumin, a phenomenon referred to as "albumin-mediated" hepatic uptake (Weisiger et al., 1981; Forker and Luxon, 1983; Bass and Pond, 1988; Tsao et al., 1988b; Meijer and van der Sluijs, 1989; Ichikawa et al., 1992) . Consequently, it has been argued that the hepatic uptake of organic anions is more efficient than can be accounted for by their unbound concentration and the "free-drug" hypothesis.
Ample evidence of the efficient elimination of organic anions has led to the proposal of several models to explain the efficient hepatic uptake. These include (1) the dissociation of ligand-albumin complexes catalyzed by their interaction with the cell surface (Forker and Luxon, 1981; Weisiger et al., 1981; Forker et al., 1982; Forker and Luxon, 1983; Tsao et al., 1988a) , (2) the rate-limiting dissociation of ligand-albumin complexes in the extracellular fluid (Weisiger et al., 1984; Weisiger, 1985; van der Sluijs et al., 1987) , and (3) the rate-limiting diffusion of ligand through the unstirred water layer adjacent 8 after being cultured for less than 22 h. The experimental protocol for the use of the animals was approved by Toho University Animal Care and Use Committee (approval number: 16-53-258) .
Uptake of ANS in primary cultured hepatocytes was measured at 37 C in uptake buffer (pH 7.5) as described previously (Masuda et al., 2014) . The composition of the uptake buffer was 140 mM NaCl, 3 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 5 mM glucose, and 10 mM Hepes/Tris adjusted to pH 7.5. Cells in each well were washed with the prewarmed uptake buffer and were preincubated for 5 min at 37 C. After aspiration of the uptake buffer, uptake was initiated by the addition of a 1-ml aliquot of uptake buffer containing ANS and BSA at various concentrations as indicated in the figure legends. At the designated time, the buffer was aspirated, and cells were immediately washed twice with ice-cold uptake buffer. The cells were then dissolved in a 1-ml aliquot of 1% (w/v) Triton-X.
The dissolved cells were diluted 10-fold with ethanol, and the samples were centrifuged at 18000 g for 10 min by a tabletop centrifuge. This aliquot of the supernatant was used to measure ANS concentration.
The fluorescence intensity resulting from ANS uptake to the cells was measured at 470 nm (excitation 370 nm) using an Enspire multiplate fluorescence reader (PerkinElmer Inc., Waltham, MA) (Sugiyama et al., 1983; Chung et al., 1990a) .
Measurement of PTV uptake by suspended human hepatocytes
The rate of uptake of PTV by suspended human hepatocytes was determined using cryopreserved human hepatocytes and a centrifugal filtration technique as described previously (Watanabe et al., This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 3, 2018 as DOI: 10.1124/dmd.117.077115 at ASPET Journals on January 29, 2018 dmd.aspetjournals.org Downloaded from 2010; Watanabe et al., 2011) . For the uptake experiments, cryopreserved hepatocytes were thawed in a water bath at 37 C then placed on ice, after which they were resuspended in Krebs-Henseleit buffer. Cell viability was determined by trypan blue exclusion, and the suspension was diluted to 2  10 6 cells/ml. Then, 150-μl aliquots of cells were placed in test plates and prewarmed in a 37 C incubator for 3 min. Uptake incubations were initiated by the addition of 150 l of prewarmed 10 M PTV, with and without HSA, which resulted in a final substrate concentration of 5 M and a cell density of 1  10 6 cells/ml in a 300-l incubation volume. After a designated time (0.25 and 1.25 min), the reactions were terminated by separating the cells from the medium using a centrifugal filtration technique. For this purpose, the 80-l aliquot of incubation mixture was placed in a 0.4-ml centrifuge tube (Sarstedt, Numbrecht, Germany) containing 50-l of 5 M ammonium acetate under a 100-l layer of an oil mixture (density 1.05, mixture of silicone oil and mineral oil; Sigma-Aldrich).
Samples were then centrifuged for 10 s in a microfuge (Beckman Coulter). During the centrifugation, the hepatocytes rapidly passed through the oil layer into the aqueous solution (5 M ammonium acetate). The tubes were frozen in liquid nitrogen immediately after centrifugation and stored at -20 C until analysis. The bottom of the tube was sliced off, and the contents were transferred to a new tube. Protein in the aqueous solution was precipitated with 3 volumes of acetonitrile/methanol (50/50, v/v) and removed by centrifugation at 15,000 g at 4 C for 10 min. The supernatants from the top (medium) and the bottom (cells) of the tube were analyzed by liquid PTV was analyzed on a Shimadzu LCMS-8050 triple quadrupole mass spectrometer (Shimadzu, Kyoto, Japan). Samples (5 l) were injected onto a Kintex C18 column (2.1  100 mm, 2.6 m;
Phenomenex, Torrance, CA) and eluted by a mobile phase with initial conditions of 5% solvent B, followed by a linear gradient of 5% solvent B to 80% solvent B over 3.0 min (solvent A, 0.1% formic acid in water; solvent B, 100% acetonitrile) at a flow rate of 0.3 ml/min. The column and autosampler tray temperature were maintained at 40 C and 4 C, respectively. For PTV, the mass spectrometer was operated in positive turbo-ion spray model at the transitions (m/z) 422 to 290.
Measurement of ANS binding to BSA by the equilibrium dialysis method
A dialysis cell comprising two chambers was divided by a 15 kDa cutoff dialysis membrane (Spectrum Medical Industries. Inc., Los Angeles, CA). Five milliliters of uptake buffer with or without added BSA was put into each chamber. ANS was added to the side containing BSA. After equilibrium was achieved at 37 C (more than 22 h), the aliquot of the sample in each cell was diluted more than 10-fold with EtOH, and ANS concentrations were measured as described above. The recovery of ANS was greater than 98%.
Measurement of PTV binding to HSA by the equilibrium dialysis method
The binding of PTV to HSA was determined using a single-use RED (rapid equilibrium dialysis) This article has not been copyedited and formatted. The final version may differ from this version. (Thermo Scientific, Rockford, IL) . In this study, PTV was added at a final concentration of 5 M to PBS (phosphate buffered saline) buffer pH 7.4 containing HSA at 0, 0.125, 0.25, 0.5 and 1%, and then incubated at 37 C for 24 h on an orbital shaker. According to the manufacturer's instructions, 300 l of the mixture was placed into the sample chamber, and the dialysis buffer (i.e., PBS, pH 7.4) was placed into the buffer chamber. After equilibrium was achieved (i.e., after 20 h), the concentrations of PTV in both chambers were measured using LC-MS/MS analysis, as described above. The recovery of PTV was approximately 92-98%.
Kinetic analyses
The initial uptake rates were calculated from the slopes of the time courses from 1 to 3 min for ANS and from 0.25 to 1.25 min for PTV, using linear regression analysis. The uptake clearances (PS u,inf and PS inf ) for unbound and total ligand concentrations were estimated by dividing the initial uptake rate by the unbound and total ligand concentrations, respectively. Saturation kinetics of the initial uptake rates were analyzed by fitting the concentration dependency of the initial uptake rate of ANS to a Michaelis-Menten-type equation with a saturable component. The kinetic parameters (V max , the maximum uptake rate; K m , Michaelis constant) were determined by an iterative nonlinear least-squares method using Sigmaplot (v.13, Systat Software Inc., San Jose, CA).
Kinetic modeling
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We used two models in this study: a conventional "free-drug" model and the "facilitated-dissociation" model (Tsao et al., 1988a) . The models used here are based on the assumption that the association and dissociation of ligand and albumin were rapid enough to achieve equilibrium.
The two models are summarized below.
A conventional model of hepatic uptake involving a transporter
In the conventional "free-drug" model ( Fig. 1) , it is assumed that rapid equilibrium of the binding of a ligand to albumin can be achieved in the extracellular bulk fluid. The hepatic uptake of the ligand is assumed to comprise transporter-mediated uptake and passive diffusion across the membrane, which correspond to the saturable and nonsaturable components, respectively, in the Michaelis-Menten equation. The uptake rate is described by the following equation:
where f c is the unbound ligand in the extracellular fluid; max V and m K represent the maximum uptake rate and Michaelis constant, respectively; and d P is the passive diffusion coefficient. Under linear conditions of transporter kinetics, Eq. 1 can be reduced to
(2)
In the initial uptake by hepatocytes, the following mass-balance equation holds:
This article has not been copyedited and formatted. The final version may differ from this version. Substituting Eq. 3 into Eq. 2 gives:
(4)
The uptake clearances for the total ligand concentration ( where the R value in the conventional model usually represents 1, irrespective of the presence of albumin.
A "facilitated-dissociation" model of the dissociation of unbound ligand from the ligand-albumin complex
In our previous study, the "albumin-mediated" hepatic transport phenomenon was characterized using isolated hepatocytes and isolated perfused liver, and was analyzed using a "facilitated-dissociation" model, in which the interaction of the ligand-albumin complex with the This article has not been copyedited and formatted. The final version may differ from this version. surface of hepatocytes enhances dissociation of the ligand from the complex (Tsao et al., 1988a; Tsao et al., 1988b) . As shown in Fig. 2 , the mechanism of this facilitation has been postulated to be that an interaction between the ligand-albumin complex and the surface of hepatocytes induces a conformational change in albumin, which results in enhancement of the dissociation of ligand from the ligand-albumin complex near the cell surface and consequently effective uptake of the ligand (Forker and Luxon, 1981; Forker and Luxon, 1983; Tsao et al., 1988a ). If we presume that the unbound albumin and the ligand-bound albumin compete for the same binding sites on the surface of hepatocytes, the fraction of albumin bound to the surface of the hepatocytes (  ) is given by the 
where 0 c represents the total concentration of ligand; Alternatively, we also analyzed the obtained data using the model derived by Forker et al. (Forker and Luxon, 1983) , which was categorized as a "facilitated-dissociation" model, but was more similar to a model based on the "albumin receptor" theory. According to this model, the ratio of PS u,inf (+) to PS u,inf (-) can be expressed, as follows:
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Extrapolation of the in vivo hepatic uptake clearance from the uptake clearance measured using isolated hepatocytes.
The unbound hepatic uptake clearances for ANS and PTV in vivo (per body weight) were scaled up from the in vitro unbound hepatic uptake clearance using the following scaling factors: 1.2  10 8 cells/g liver, 40.0 g liver/kg body weight for rat, and 25.7 g liver/kg body weight for human (Davies and Morris, 1993; Miyauchi et al., 1993) .
In vivo hepatic overall intrinsic clearance, which represents the elimination of unbound ligands ( vivo all int, u, h, CL ) from circulating blood, was also estimated from the in vivo hepatic clearance using a dispersion model as follows: , 1993) . The N D value was set at 0.17.
The hepatic uptake clearance in vivo was estimated based on Eqs. 14-17, using the dispersion model described previously (Roberts and Rowland, 1986; Iwatsubo et al., 1996) .
Results

Initial uptake rate of ANS by primary cultured rat hepatocytes in the absence and presence of BSA
The uptake rate of ANS by primary cultured rat hepatocytes in the absence of BSA was measured, and the results are summarized in Fig. 3 . The ANS uptake increased linearly over 3 min, and the initial uptake rate was determined from the uptake over 1-3 min. The relationship between the initial uptake rate and concentration of ANS showed saturation, and the data fit the Michaelis-Menten equation describing a single saturable process; this was supported by the linearity of the Eadie-Hofstee plot shown in the inset. The kinetic parameters K m (Michaelis-Menten constant) and V max (maximal uptake rate) were 53.7  18.2 M and 3.7  0.8 nmol/min/mg protein, respectively ( calculated SD). These estimated K m and V max values were similar to those reported for isolated rat hepatocytes (Chung et al., 1990a ). The ANS uptake by primary cultured hepatocytes determined in the presence of various concentrations of BSA is summarized in Fig. 4 . ANS binds avidly to albumin, and the presence of BSA caused a remarkable decrease in its uptake. The hepatic uptake clearance (PS inf ) and the unbound uptake clearance (PS u,inf ) were estimated by dividing the uptake rate by the initial concentration and unbound concentrations, respectively, and are depicted in Fig. 5 and summarized in Table I (a) . First, to confirm whether the ANS uptake by Oatp was linear within the range of 20 M, we determined the ANS uptake rates at various concentrations of ANS. As shown in Fig. 4 , the hepatic uptake clearances for ANS in the range of 2-20 M remained unchanged (did not differ significantly), being consistent et al., 1981) , who were the first to propose the "albumin receptor" theory.
The unbound concentrations were determined using the equilibrium dialysis method. The PS inf value of ANS decreased markedly as the concentration of BSA increased, in association with the decrease in the unbound fraction. In contrast, the PS u,inf value of ANS was enhanced markedly as the concentration of BSA increased, although the unbound concentration was kept at approximately 2.4 M (Fig. 5 (b) ).
In other words, the PS u,inf value in the presence of albumin was much higher than could be accounted for by the unbound concentration. The extent of the enhancement in the PS u,inf values was saturated at the highest concentration of BSA. These kinetic features are distinctive of the "albumin-mediated" hepatic transport phenomenon (Weisiger et al., 1981; Forker and Luxon, 1983) . M, although the BSA concentrations were increased. Both experimental conditions demonstrated similar relationships between the albumin concentration and PS u,inf enhancement, as shown below (Fig.   8 (a) ).
Initial uptake rate of PTV by isolated human hepatocytes in the absence and presence of HSA
The rate of uptake of PTV by isolated human hepatocytes was measured in the absence and presence of HSA, and the results are summarized in Fig. 7 and Table I (b) . The PTV uptake increased linearly over 1.5 min, and the initial uptake rate was determined from the uptake over 0.25-1.25 min. Similar to ANS uptake by primary cultured rat hepatocytes, the PS inf value was estimated by dividing the uptake rate by the initial concentration. The PS inf value of PTV decreased substantially as the concentration of HSA increased. In contrast, the PS u,inf value clearly increased as the HSA concentration increased, and the PS u,inf values were saturated at 1% (w/v) HSA. Therefore, the "albumin-mediated" hepatic transport phenomenon was also observed in the uptake of PTV by human hepatocytes, known to be mediated by OATP1B1 (Watanabe et al., 2010) .
Analysis by the previous "facilitated-dissociation" model of the albumin dependency of the ratio of the unbound uptake clearance in the presence of albumin to that in its absence (R)
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The "facilitated-dissociation" model is well known to describe adequately the hepatic uptake rate of a highly bound ligand in the presence of albumin (Forker and Luxon, 1981; Forker and Luxon, 1983; Tsao et al., 1988a) . We therefore performed curve fitting of the albumin concentration-dependency of the R values ( Fig. 8) , based on Eq. 12. The "facilitated-dissociation" model provided adequately fitting curves for the albumin dependency (Fig. 8) 
K
for PTV were estimated to be 48.8  11.6 M and 199  61 M ( calculated SD), respectively (Table II) . As an alternative, we analyzed the albumin concentration-dependency of the R values using the model developed by Forker et al (Forker and Luxon, 1981; Forker and Luxon, 1983) . As shown in supplementary Fig. 1, this Table I ).
Extrapolation of the in vivo hepatic uptake clearance from the in vitro hepatic uptake clearance obtained using isolated hepatocytes
22
The in vivo hepatic uptake clearances of unbound ligand for ANS and PTV ( vitro inf u, PS ) were extrapolated from the in vitro hepatic uptake clearance obtained using isolated hepatocytes, and the results are summarized in Table II . The values of 
Discussion
In this study, we used primary cultured rat hepatocytes and isolated human hepatocytes to determine whether BSA and HSA enhanced the PS u,inf of ANS and PTV, respectively. These organic anions have been shown to be taken up by the liver via a transporter-mediated process (Sugiyama et al., 1983; Chung et al., 1990a; Chung et al., 1990b; Watanabe et al., 2010; Watanabe et al., 2011; Kimoto et al., 2012) . As shown in Figs 5 and 6 , the presence of albumin prominently enhanced PS u,inf values of hepatocytes. This enhancement of the PS u,inf values was saturated at high concentrations of albumins, indicating that the "albumin-mediated" hepatic uptake phenomenon was being observed in rat and human hepatocytes (Figs 5 (b) and 6 (b)).
As discussed earlier, several mechanisms have been proposed to account for the enhancement of the hepatic uptake clearance of unbound ligand. In the present study, the "albumin-mediated" hepatic uptake transport of ANS and PTV was analyzed using a "facilitated-dissociation" model, in which contact of the ligand-albumin complex with the surface of hepatocytes enhances the dissociation of the ligand from the complex and provides the hepatocytes with more unbound ligand for uptake (Fig. 2) . We therefore performed curve fitting using the governing equation, Eq. 12. The calculated line fitted well compatible with those reported in other studies (Weisiger et al., 1981; Forker and Luxon, 1983; Elmadhoun et al., 2001) . Various models previously proposed can explain the kinetic features; the albumin-dependent enhancement of PS u,inf and its saturation in the presence of higher concentrations of albumin and provide the enhancement ratio of PS u,inf in the presence of physiological concentrations of albumin, although it is difficult to distinguish the most adequate of the various models. Among these model, the "facilitated-dissociation" model developed by Forker et al. (Forker and Luxon, 1983) was most similar to a model based on the albumin receptor theory. The model also provided a good prediction of the relationship between the enhancement of PS u,inf and the albumin concentrations (supplementary Fig. 1) , with K d,m values of 30 M and 300 M, respectively (supplementary Table I) , compatible with our model. Either mechanism can explain the kinetic features of the albumin-mediated hepatic uptake and the enhancement ratio of PS u,inf value under physiological levels of albumin. Blitzer and Lyons (Blitzer and Lyons, 1985) directly demonstrated, using rat basolateral liver plasma membrane vesicles, that albumin enhanced Na + -dependent bile acid uptake. They proposed as a possible mechanism that the binding of albumin-bile acid complex to the liver plasma membrane might facilitate the interaction of bile acid with its transporter and enhance the bile acid available for uptake, implying that the fractions in the blood were similar. According to a kinetic study by Blitzer and Lyons (Blitzer and Lyons, 1985) , albumin reduced the bile-acid transporter K m value; in other words, the binding of albumin to the liver plasma membrane enhanced the affinity of the bile acid for its transporter. PTV shows a relatively high affinity for OATP (Kimoto et al., 2012) , whereas ANS shows a relatively low affinity for Oatp (Chung et al., 1990b) , leading us to hypothesize that the higher the affinity for the transporter, the more effective is the albumin-mediated enhancement. Further development of another model including the interaction between the albumin-organic anion complex and the transporter is required to demonstrate its mechanism.
There are several published reports concerning the interaction of albumin with the surface of using several proteins including modified albumins, demonstrated that an ionic interaction between extracellular protein and hepatocytes occurs at the cell surface, which enhances palmitate uptake by hepatocytes (Burczynski et al., 2001; Elmadhoun et al., 2001) . However, the physiological and biochemical relevance of this interaction remains unknown, and its mechanism requires further investigation.
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Recently, based on the "free-drug" hypothesis, quantitative IVIVE of hepatic uptake clearance using cryopreserved human hepatocytes resulted in good predictions of the uptake of some organic anions (Watanabe et al., 2010) . However, the uptake of other organic anions that bind avidly to serum albumin was poorly predicted (Watanabe et al., 2010; Watanabe et al., 2011) . Hypothesizing that the "albumin-mediated" hepatic uptake mechanism might be a factor in these poor predictions, we estimated the R values in physiological albumin concentrations (5% albumin) on the basis of the "facilitated-dissociation" model. The R values for ANS and PTV were estimated to be 2.7 and 11, respectively, implying that the albumin-mediated hepatic uptake mechanism should be considered in vivo. Furthermore, the unbound hepatic uptake clearances ( vitro inf u, PS ) for ANS and PTV in vivo (per body weight) were extrapolated from the in vitro unbound hepatic uptake clearances (Davies and Morris, 1993) to be 260 ml/min/kg and 83 ml/min/kg, respectively ( Table 2 ). The hepatic uptake clearance ( vivo all int, u, h,
CL
) was estimated from in vivo kinetic parameters using a dispersion model, as described previously (Roberts and Rowland, 1986; Iwatsubo et al., 1996) 
PS
for ANS and PTV were estimated to be 3 and 18, respectively, indicating that the huge discrepancy seen in IVIVE could be attributed mainly to "albumin-mediated" hepatic uptake and could be largely corrected by using the R value estimated with the "facilitated-dissociation" model. In the present study, however, IVIVE taking into account the albumin-mediated hepatic uptake provided good This article has not been copyedited and formatted. The final version may differ from this version. predictions for only the two organic anions ANS and PTV; therefore, further investigations of other organic anions that are highly bound to albumin are required to elucidate how albumin-mediated hepatic uptake might be involved in IVIVE.
Alternative reasons also could be considered to raise poor predictions of IVIVE; (i) pH difference between intracellular and extracellular spaces (Poulin and Haddad, 2015) , ii) the concentration difference in between the plasma and liver (Poulin et al., 2016) , iii) the activity heterogeneity of the human cryopreserved hepatocytes (Badolo et al., 2011) , and (iv) the kinetic model describing the behavior of anion in the liver (Iwatsubo et al., 1996) . Poulin et al. (Poulin et al., 2016) developed a useful procedure for quantifying the unbound ligand concentration under in vivo conditions by taking into account pH difference between intracellular and extracellular spaces and the concentration difference in between the plasma and liver and pH-partition mechanisms. This empirical method provides an improvement of quantitative IVIVE for a range of drugs that bind avidly to albumin (Poulin et al., 2012; Poulin and Haddad, 2015; Poulin et al., 2016) . Very recently, Bounakta et al. (Bounakta et al., 2017) and Poulin et al. (Poulin et al., 2017) demonstrated using an isolated perfused rat liver system that the IVIVE method based on the albumin-mediated uptake mechanism provideed the most accurate predictions of in vivo hepatic clearance as compared with other empirical IVIVE considering pH and albumin concentration differences between the plasma and liver. Thus, it is important to note that a kinetic model for describing the "albumin-mediated" hepatic uptake phenomenon for a ligand avidly bound to albumin is This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 3, 2018 as DOI: 10.1124 at ASPET Journals on January 29, 2018 dmd.aspetjournals.org
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indispensable for its robust IVIVE.
In conclusion, we have demonstrated that the unbound hepatic uptake clearance of the organic anions ANS and PTV was substantially enhanced by the presence of albumin and that this enhancement was saturated at a high concentration of albumin. Therefore, "albumin-mediated" hepatic transport was demonstrated to play a role in uptake of these anions by rat and human hepatocytes. The relationship between the enhancement of the unbound hepatic clearance and the albumin concentration could be accurately predicted by the "facilitated-dissociation" model constructed previously, in which the interaction of the ligand-albumin complex with the cell surface enhances the dissociation of the complex to make unbound ligand available for uptake to the hepatocytes. By considering this enhancement of hepatic uptake clearance by albumin, we could also predict the uptake clearance in vivo from that observed in isolated hepatocytes. In light of these findings, we propose that the "facilitated-dissociation" model can be applied to describing the phenomenon of "albumin-mediated" hepatic uptake via organic anion transporters and to evaluating hepatic uptake clearance in vivo.
This article has not been copyedited and formatted. The final version may differ from this version. c to f c is designated as  . The uptake rate of a ligand is presumed to be governed not only by transport-mediated uptake but also by passive diffusion uptake (Eq. 1).
Figure 2 The "facilitated-dissociation" model
The uptake of highly albumin-bound ligands to hepatocytes comprises a pathway for the unbound ligands and an additional pathway for the albumin-bound ligands. The interaction of the ligand-albumin complex with the surface of hepatocytes makes more unbound ligand available for uptake than would be expected according to the conventional model. It was assumed that the unbound and ligand-bound albumin compete for the same binding site(s) on the surface of hepatocytes with the same affinity (dissociation constant, K d,m ).
Figure 3 Concentration-dependency of ANS uptake by primary cultured rat hepatocytes
Panel ( 
Figure 4 Effect of BSA on ANS uptake by primary cultured rat hepatocytes
The uptake of ANS was measured for 3 min at 37 C and pH 7.5. Each point represents the mean  SE (n = 4).
Figure 5 The effect of BSA on unbound uptake clearance (PS u,inf ) of ANS by rat hepatocytes
Panel (a): Uptake clearance (PS inf ) of ANS. The uptake clearance was estimated by dividing the uptake rate by the ANS concentration in the medium (Fig. 4) . Enhancement of the unbound uptake clearance of ANS was saturated at higher concentrations of BSA.
Comparison of the uptake clearances in the presence and absence of albumin were performed with Student's t-test. (*), significantly different from control (P < 0.05); (**), significantly different from control (P < 0.01).
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